91 Startups
  • Sector
  • Participated in
  • Year of participation

Hubrecht Organoid Technology (The HUB)

  • 2010
  • Enabling Technology
  • Other
the HUB provides access to a unique and robust platform that links patient-specific genetic and phenotypic information to preclinical and clinical drug-responsiveness.

Hy2Care

  • 2011
  • Other
  • Therapeutics
Hy2Care develops a so called “injectable plaster” to repair the cartilage surface.

Hybridize

  • 2018
  • Venture Challenge
At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

IMcoMet

  • 2019
  • Therapeutics
  • Venture Challenge
Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.

Incircular biotechnologies

  • 2019
  • Enabling Technology
  • Venture Challenge
Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Innofuse

  • 2014
  • Medical Device
  • Venture Challenge
An infusion set that guarantees stability and immediacy of drug administration for preterm babies

IS-Diagnostics

  • 2010
  • Diagnostics
  • Other
The next generation of clinical diagnostics

JETA molecular

  • 2016
  • Enabling Technology
  • Other
Design, development and commercialization of noninvasive reagent and software solutions for transplant monitoring

Karveel

  • 2015
  • Therapeutics
  • Venture Challenge
To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.

Khondrion

  • 2010
  • Other
  • Therapeutics
Khondrion is a clinical stage pharmaceutical company focusing on the development of treatments for mitochondrial (-related) diseases and conditions